https://charts.traderzeitung.de/phases/US22053A2069
string(1429) "{"isin":"US22053A2069","name":"Quince Therapeutics Inc","stock_id_xnas":132475783,"stock_id_xnys":132475784,"generated_at":"2026-09-22 23:59:00","days":[{"date":"2026-09-18","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":29.49,"close_at":"2026-09-18 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":30.665,"close_at":"2026-09-21 21:59:00","complete":true,"perf_pct":3.9844},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":29.99,"close_at":"2026-09-21 22:42:00","complete":true,"perf_pct":-2.2012}]},{"date":"2026-09-22","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":31.31,"close_at":"2026-09-22 21:59:00","complete":true,"perf_pct":4.4015},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":false,"perf_pct":null}]}]}"
Quince Therapeutics Aktie News & Nachrichten

Quince Therapeutics Aktie News & Nachrichten

[WKN: A428L6 | Symbol: QNCX]
Realtimekurs
   
Quince Therapeutics, Inc. is a biopharmaceutical company, which engages in the unlocking the power of a patient’s biology for the treatment of rare diseases. Its product includes EryDex, developed using their proprietary Autologous Intracellular Drug Encapsulation (AIDE) technology platform, which is a novel device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.
Vorbörsliche Indikationen
Regulärer Handel
Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Quince Therapeutics: Strategischer Neustart rückt seltenes Lungenleiden in den Fokus der Investoren

Die Übernahme von Orphai Therapeutics leitet einen Fokuswechsel auf seltene Lungenerkrankungen ein und...

  • 1
MT Newswires 21.08.2026 12:24 Uhr

Craig-Hallum bewertet Quince Therapeutics neu mit Buy und einem Kursziel von 68 USD

06:23 AM EDT, 21.08.2026 (MT Newswires) -- Quince Therapeutics (QNCX) hat laut von FactSet befragten Analysten ein durchschnittliches Rating von Buy u

MT Newswires 29.07.2026 14:55 Uhr

--Oppenheimer bewertet Quince Therapeutics neu mit Outperform und einem Kursziel von 82 US-Dollar

08:54 AM EDT, 07/29/2026 (MT Newswires) -- http://www.mtnewswires.com Copyright © 2026 MT Newswires. All rights reserved. MT Newswires does not provid

MT Newswires 24.06.2026 13:44 Uhr

Leerink Partners stuft Quince Therapeutics mit Outperform und einem Kursziel von $4 ein

07:37 AM EDT, 06/24/2026 (MT Newswires) -- http://www.mtnewswires.com Copyright © 2026 MT Newswires. All rights reserved. MT Newswires does not provid

MT Newswires 23.06.2026 13:07 Uhr

--Cantor Fitzgerald Initiates Quince Therapeutics at Overweight With $4 Price Target

07:05 AM EDT, 06/23/2026 (MT Newswires) -- http://www.mtnewswires.com Copyright © 2026 MT Newswires. All rights reserved. MT Newswires does not provid